Gossamer Bio to Showcase Seralutinib at Cantor Healthcare Conference
Event summary
- Gossamer Bio (Nasdaq: GOSS) will present at the Cantor Global Healthcare Conference on September 9, 2026, at 10:55 AM ET.
- The presentation will focus on seralutinib, its lead candidate for pulmonary arterial hypertension (PAH) and PH-ILD.
- Format includes a presentation and one-on-one meetings.
- Event will be webcast, but no specific link provided in the release.
The big picture
Gossamer Bio's participation in the Cantor Global Healthcare Conference underscores its push to secure investor confidence amid a competitive landscape in pulmonary hypertension treatments. The event comes at a critical juncture as the company advances seralutinib through clinical stages, with broader implications for its market positioning and potential partnerships.
What we're watching
- Clinical Progress
- How seralutinib's development timeline will be addressed and whether new data will be shared.
- Investor Sentiment
- Whether the presentation shifts market perception of Gossamer Bio's valuation.
- Competitive Positioning
- The pace at which Gossamer Bio can differentiate seralutinib in the PAH and PH-ILD space.